Sinonasal NK/T-cell lymphoma

被引：13

作者：

Hmidi, M. ^{[1
]}

Kettani, M. ^{[1
]}

Elboukhari, A. ^{[1
]}

Touiheme, N. ^{[1
]}

Messary, A. ^{[1
]}

机构：

[1] Hop Mil My Ismail, Serv ORL & Chirurg Cervicofaciale, Meknes, Morocco

来源：

EUROPEAN ANNALS OF OTORHINOLARYNGOLOGY-HEAD AND NECK DISEASES | 2013年 / 130卷 / 03期

关键词：

Lymphoma; Extranodal NK/T-cell; Sinonasal; Immunohistochemistry; NASAL TYPE; T-CELL;

D O I：

10.1016/j.anorl.2012.01.005

中图分类号：

R76 [耳鼻咽喉科学];

学科分类号：

100213 ;

摘要：

Introduction: Nasal NK/T-cell lymphoma is a rare but well-known clinical entity. Thanks to improvements in anatomopathology and the development of routine immunohistochemistry, the diagnosis of nasal NK/T-cell lymphoma (NK for "natural killer") was recognized by the WHO in 2001. The main differential diagnosis is with Wegener's granulomatosis. Treatment is based on radiotherapy and chemotherapy. Prognosis is poor, with variable evolution and sometimes rapid progression. Case report: The authors report the case of a 54-year-old man without known pathological history, who presented with bilateral nasal obstruction with purulent rhinorrhea. Diagnosis was made on the basis of immunohistochemical study of biopsy samples. The tumor was graded IE on the Ann Arbor classification. Treatment, comprising CHOP chemotherapy followed by radiotherapy, achieved total remission at 8 months' follow-up. Discussion/Conclusion: Sinonasal NK/T-cell lymphoma is rare. Diagnosis is based on immunophenotypic and molecular characteristics. It is an aggressive lymphoma, requiring multidisciplinary management. Prognosis is poor. (C) 2012 Elsevier Masson SAS. All rights reserved.

引用

页码：145 / 147

页数：3

共 10 条

[1]

Cheze S, 1996, ETUDE CLIN ANATOMOPA

[2] Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index [J].

Chim, CS ;

Ma, SY ;

Au, WY ;

Choy, C ;

Lie, AKW ;

Liang, R ;

Yau, CC ;

Kwong, YL .

BLOOD, 2004, 103 (01) :216-221

[3]

Forcioli J, 2005, EMC OTORHINO LARYNGO, V2, P390, DOI [10.1016/j.emcorl.2005.09.002, DOI 10.1016/J.EMCORL.2005.09.002]

[4]

Harabuchi Y, 1996, CANCER, V77, P2137, DOI 10.1002/(SICI)1097-0142(19960515)77:10<2137::AID-CNCR27>3.0.CO

[5]

2-V

[6] Treatment outcome of angiocentric T-cell and NK/T-cell lymphoma, nasal type: Radiotherapy versus chemoradiotherapy [J].

Kim, K ;

Chie, EK ;

Kim, CW ;

Kim, ILH ;

Park, CIL .

JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2005, 35 (01) :1-5

[7]

Lachiver X, 1995, Ann Otolaryngol Chir Cervicofac, V112, P234

[8]

Mestiri S, 2008, Ann Otolaryngol Chir Cervicofac, V125, P188, DOI 10.1016/j.aorl.2008.07.003

[9] NK/T-cell lymphomas 'nasal type':: an Italian multicentric retrospective survey [J].

Pagano, L ;

Gallamini, A ;

Trapè, G ;

Fianchi, L ;

Mattei, D ;

Todeschini, G ;

Spadea, A ;

Cinieri, S ;

Iannitto, E ;

Martelli, M ;

Nosari, A ;

Bona, ED ;

Tosti, ME ;

Petti, MC ;

Falcucci, P ;

Montanaro, M ;

Pulsoni, A ;

Larocca, LM ;

Leone, G .

ANNALS OF ONCOLOGY, 2006, 17 (05) :794-800

[10] Radiation therapy versus chemotherapy as initial treatment for localized nasal natural killer (NK)/T-cell lymphoma: a single institute survey in Taiwan [J].

You, JY ;

Chi, KH ;

Yang, MH ;

Chen, CC ;

Ho, CH ;

Chau, WK ;

Hsu, HC ;

Gau, JP ;

Tzeng, CH ;

Liu, JH ;

Chen, PM ;

Chiou, TJ .

ANNALS OF ONCOLOGY, 2004, 15 (04) :618-625

← 1 →